PERRIGO Co plc

Drug pipeline (65)

Asset	Stage	Revenue	Trials	Status
Acetaminophen	approved	—	78	approved
Aspirin	approved	—	25	approved
Betamethasone Dipropionate	approved	—	0	—
Betamethasone Valerate	approved	—	0	—
Brimonidine tartrate	approved	—	11	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (7)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01744106	phase3	completed	2012-11-01	2016-04-01	Perrigo Company	A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold
NCT00802828	phase1	completed	2004-06-01	2004-06-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions
NCT00803192	phase1	completed	2004-06-01	2004-06-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fed Conditions
NCT00804440	phase1	completed	2004-01-01	2004-01-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions
NCT00803946	phase1	completed	2003-11-01	2003-11-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions

FDA applications (147)

Application

Type

Applicant

Products

ANDA 040167

ANDA

L PERRIGO CO

ANDA 062186

ANDA

PERRIGO NEW YORK INC

ANDA 062280

ANDA

PERRIGO NEW YORK INC

ANDA 064136

ANDA

PERRIGO CO OF TENESSEE INC

ANDA 070053

ANDA

PERRIGO NEW YORK INC